logo
Smoke-free future: How youth are taking the lead against nicotine addiction

Smoke-free future: How youth are taking the lead against nicotine addiction

Indian Express6 hours ago

Then just 12 years old, Agamroop Kaur realised that many of her classmates at Canyon Middle School, California, were using e-cigarettes and even noticed a distinct smell in the school bathroom—prompting this young champion to launch an anti-tobacco campaign.
Eight years on, the Indian-origin, US-based 20-year-old has not only made an impact but is among the youth ambassadors for the campaign on tobacco-free kids. At the World Conference on Tobacco Control at Dublin, Kaur as a youth ambassador has been engaged actively in various sessions talking about the power of education and advocacy as the driving force to find solutions for the e-cigarette epidemic.
As per the WHO Global Tobacco Epidemic Report 2025, there has been a growing trend to regulate the use of e-cigarettes of ENDS – Electronic Nicotine Delivery Systems. The number of countries regulating or banning ENDS has grown from 122 in 2022 to 133 in 2024, a clear signal of increased attention to these products. However over 60 countries till lack any regulations on ENDS.
Dr Ruediger Krech, director of Health Promotion, WHO, said while significant strides have been made in protecting people from the harmful effects of tobacco, much more needs to be done. Voices of youth is important in this fight and, according to Kaur, collectively there is a power for greater change.
Kaur has not only authored op-ed articles, produced a documentary on youth e-cigarettes epidemic but she has made it a mission to educate peers about the dangers of vaping. She worked persistently on successful campaigns in five California cities and Contra Costa County to end the sale of flavoured e-cigarettes. In 2022, she was presented several awards for being a tireless champion for the right to breathe smoke free air. She received the 2022 Barrie's Fiske National Youth Advocate of the Year and strongly feels that the future of tobacco control is youth powered.
Currently pursing a major in Cognitive Science and Global Health at UCLA, Kaur has also served on the Board of Directors for public health NGOs and has spoken on global panels for several organisations including the United Nations, CDC and World Heart Federation.
'We have faced several challenges as the tobacco industry challenged the bill that had proposed a ban on tobacco products. But we persisted and the bill was eventually passed,' Kaur recalled.
At the conference at Dublin, among other young ambassadors working on tobacco control and mobilising youth to protect their generation from the harms of tobacco and nicotine addiction include Lisa Lu, who is a senior at Stanford University, studying to be a lawyer and who set up the International Youth Tobacco Control, and Manik Marganamahendra, Executive Director of Indonesia Youth Council for Tactical Challenges who received the 2025 Global Young Ambassador of the Year award.
'The best way to promote education about tobacco and its harmful usage is to reach out to students in a simple and easy to understand format. We need to speak their language so that they feel more involved,' said Manik who began his involvement in tobacco control a decade ago at the University of Indonesia where he led student protests on opposing legislations that favoured the tobacco industry.
Lisa, 22, too has a played a key role in advocating for a new law prohibiting the sale of flavoured tobacco products in Los Angeles county. She remembers the time when she travelled to China and conducted a survey of 857 students. Witnessing a culture of teenage smoking she set up the IYTC and expanded the organisation to 60 countries. 'There are several challenges but we need to invest in young voices and lead the fight against tobacco,' she said while Gene Gesite Jr. from Philippines spoke about challenges he faced as he grew up surrounded by friends who found smoking very cool. Now as the coordinator of the Global Youth Voices the focus is getting more organisations onboard to step up the fight against nicotine addiction.
Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition.
... Read More

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

World's first kids' malaria vaccine price to be less than USD 5 by 2028
World's first kids' malaria vaccine price to be less than USD 5 by 2028

United News of India

time2 hours ago

  • United News of India

World's first kids' malaria vaccine price to be less than USD 5 by 2028

Hyderabad, June 25 (UNI) Bharat Biotech International Limited (BBIL) and GSK plc, a Global Pharma Company, today announced their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world's first malaria vaccine. Bharat Biotech will be reducing the price of world first malaria vaccine 'RTS.S, developed by GSK, PATH and partners, by more than half, to less than $5 progressively by 2028. This price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, Hyderabad based vaccine maker BBIL said in a release here. The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. RTS,S was the first malaria vaccine recommended by the World Health Organisation (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. In parallel, Bharat Biotech has invested over $200 million in new, higher- output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete. Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025 This has only been possible through the critical work that GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa. BBIL Executive Chairman Dr. Krishna Ella, said: "Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria'. In a recent evaluation of impact by the WHO of the Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya and Malawi, where over 2 million children received the RTS,S vaccine between 2019 and 2023, the WHO reported a 13 percent reduction in all-cause mortality and a 22 percent reduction in hospitalisations of severe malaria among children age- eligible for vaccination during this period1. When administered seasonally in regions with high malaria transmission, alongside seasonal malaria chemoprevention, the two malaria vaccines recommended by the WHO, have been shown to prevent around 75 percent of malaria episodes. UNI KNR SSP

From The Hindu, June 26, 1925: Disease incidence in India
From The Hindu, June 26, 1925: Disease incidence in India

The Hindu

time2 hours ago

  • The Hindu

From The Hindu, June 26, 1925: Disease incidence in India

At the Congress of the Royal Sanitary Institute held at Brighton, London, Sir Leonard Rogers gave a paper on disease incidence and climate in India, which drew deductions from Indian data of great importance in connection with the serious increase in the percentage of unvaccinated children in Great Britain. Sir Leonard Rogers said, as reported by 'The Englishman' correspondent, that the well marked dry cold, dry hot and hot moist, rainy seasons in India, and the great variations in the rainfall in different areas, together with the carefully recorded vital statistics for several decades, furnished an ideal field for studying the influence of climatic conditions on disease incidence. He had shown in previous publications a very close relationship between high rainfall and high leprosy incidence, and vice versa, all over India, and also between humid monsoon winds and high orthosis rates which he illustrated by maps. He also demonstrated in a similar manner the closest relationship between low minimum temperatures, low humidity, and great diurnal variations of temperature during the cold season in the North.

Hope for AML patients with rare gene mutation
Hope for AML patients with rare gene mutation

Time of India

time4 hours ago

  • Time of India

Hope for AML patients with rare gene mutation

Pune: New and emerging therapies, which cause less collateral damage to normal blood and target specific mutations, are a promising alternative to treat Acute Myeloid Leukemia (AML), several oncologists have said. June is AML awareness month. Specialists have begun using ivosidenib, one such drug, that targets AML with IDH mutation, after Central Drugs Standard Control Organisation approved it in May. You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune India accounts for the highest number of AML cases after the US and China as per statistics from 2021. Dr Sameer Melinkeri, clinical haematologist at Pune's Deenanath Mangeshkar Hospital & Research Centre, said new therapies such as ivosidenib, azacitidine and venetoclax, help precisely target individual mutations in AML. "Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri. "It blocks a faulty enzyme—mutant IDH1—that causes the buildup of a harmful substance called 2-hydroxyglutarate in the body. This substance stops blood cells from maturing and spreads cancer cells," the doctor added. He said ivosidenib turns off the cancer-causing switch (mutation) in patients with IDH, a specific gene mutation. By stopping the enzyme, ivosidenib helps blood cells mature normally, reducing cancerous cells and allowing healthy cells to grow. Dr Reshma Puranik, a medical and haemato-oncologist with MOC, Cancer Care and Research Centre said that ivosidenib is a first-in-class, oral, small-molecule inhibitor of the mutant IDH1 enzyme and works well in brain tumors with IDH mutation. In trials, ivosidenib and azacitidine achieved superior outcomes with similar toxicity compared to azacitidine with newly-diagnosed IDH1-mutated AML. "Patients on ivosidenib need to monitor blood counts along with renal and liver function tests, serum electrolytes and QT interval on ECG. Some patients get a minor rash, feel fatigued, have oral mucositis (ulcers) and are at risk of differentiation syndrome," Dr Puranik added. While the new targeted therapies are expensive, more awareness and distributors in the market will bring the cost down, experts say. Dr Shilpa Gupta, consultant haemato-oncologist in a Mumbai-based cancer centre, said, "I have started ivosidenib for a patient and will wait for the results."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store